NDA 050747 · King Pharms
Synercid
Quinupristin, Dalfopristin · Injection
NovelAccelerated approvalPriority reviewLast checked: Nov 19, 2026Latest source record: Jun 16, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Sep 21, 1999
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SYNERCID · QUINUPRISTIN 500MG; DALFOPRISTIN · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Quinupristin" as an intervention, any sponsor and status, largest first.
Julio RamirezAcademic, hospital or other
NCT02099240 · 11 participants · Start Mar 6, 2014 · Primary completion Nov 7, 2018
Drug: oral antibiotics · For: Osteomyelitis
Sites: Louisville, Kentucky
- Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric PatientsPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT00240747 · Start Jun 2000
Drug: Synercid · For: Gram-Positive Bacterial Infections
Sites: Oakland, California; Orange, California; Durham, North Carolina · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis.
Guan L, Beig M, Wang L, et al. · Ann Clin Microbiol Antimicrob 2024 · Systematic Review, Meta-Analysis
- MRSA: treating people with infection.
Nathwani D, Davey PG, Marwick CA · BMJ Clin Evid 2010 · Systematic Review
- Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (Synercid) in healthy volunteers.
Chevalier P, Rey J, Pasquier O, et al. · J Clin Pharmacol 2001 · Clinical Trial, Clinical Trial, Phase I
- Successful administration of quinupristin/dalfopristin in the outpatient setting.
Rehm SJ, Graham DR, Srinath L, et al. · J Antimicrob Chemother 2001 · Clinical Trial, Research Support, Non-U.S. Gov't
- Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients.
Johnson CA, Taylor CA, Zimmerman SW, et al. · Antimicrob Agents Chemother 1999 · Clinical Trial, Research Support, Non-U.S. Gov't
- Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.
Nichols RL, Graham DR, Barriere SL, et al. · J Antimicrob Chemother 1999 · Clinical Trial, Clinical Trial, Phase III
Sponsor: King Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.